Centrus's stock price soared 9.10% during intraday trading on Wednesday, marking a significant recovery in the session.

The rally appears to be a strong rebound from the prior session's selloff, which was triggered by the company's SEC-disclosed extension of a key construction contract performance period. While the contract extension initially raised concerns over project timelines, the broader policy narrative has continued to underpin bullish sentiment for the stock.

Centrus is viewed as a core beneficiary of the U.S. government's accelerated effort to rebuild domestic uranium enrichment capacity, driven by energy security imperatives. As one of the few U.S.-based companies with high-assay low-enriched uranium (HALEU) mass production capability, Centrus has secured multiple Department of Energy contracts and restarted centrifuge manufacturing, positioning itself along the policy mainline of nuclear fuel self-sufficiency.